Jyong Biotech Ltd.

About Jyong Biotech Ltd.

Jyong Biotech is dedicated to pioneering new solutions for urinary system diseases, with a focus on discovering and developing innovative medicines to address significant unmet medical needs worldwide. With over 20 years of experience, they have achieved breakthroughs ready to be shared.

Products & Services

Botreso(r) (MCS-2):A plant-derived drug candidate for treating benign prostate hyperplasia (BPH) and lower urinary tract (LUT) symptoms. Currently in FDA clinical trials, it offers a personalized, effective solution with fewer side effects, non-invasive treatment, fast symptom relief, and long-term benefits.

Specialties

Urinary system diseases Benign prostate hyperplasia (BPH) treatment Lower urinary tract (LUT) symptoms treatment Plant-derived drug development Clinical trials for innovative medicines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 20000000 MR: - FA: approximately $20 million FAN: 20000000	D: 2025-06-18 FD: 2025-06-18	1 investors
2	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2025-06-16 FD: 2025-06-16	1 investors

Initial Public Offering Latest

2025-06-18

$20.0M

1 investor (Pro only)

Initial Public Offering 2025-06-16

$20.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News